Get started
Author

Shuji Chiba

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy
2022 · Shintaro Narita, Takahiro Kimura, et al. · World Journal of Urology · 19
Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
2022 · Shintaro Narita, Takahiro Kimura, et al. · International Journal of Clinical Oncology · 13
Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan
2021 · Yumina Muto, Shintaro Narita, et al. · Medical Oncology · 8
Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
2024 · Shintaro Narita, Takafumi Yanagisawa, et al. · The Prostate · 7
Hemodialysis initiation for a case of end-stage renal disease with hemorrhagic-acquired F13 deficiency
2015 · Sohei Kanda, Mitsuru Saito, et al. · Nihon Toseki Igakkai Zasshi · 1
PDF
[The Initial Results of Robot-Assisted Pyeloplasty in Comparison with Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction].
2020 · Mizuki Kobayashi, Takamitsu Inoue, et al. · PubMed
PDF
[Two Cases of Urinary Retention with Prostatic Abscess Drained by Transurethral Resection].
2016 · Yoshinori Matsuda, Takamitsu Inoue, et al. · PubMed
PDF
1168 Survivin Polymorphisms and Expression Are Associated With Bladder Cancer Susceptibility and Progression
2010 · Naoko Kawata, Yohei Horikawa, et al. · The Journal of Urology
Works count: 8
Citation count: 48
H-index: 4
I10-index: 2
Year
Topic
Type